Blue Star Opportunities considering acquisition in Clinical AI

RENO, NV, April 9th, 2024. Blue Star Opportunities Corp. (The "Company") (OTC: BSTO),

announces today negotiations towards the acquisition of a new line of business in the field of AI clinical analytics intelligence. The company was presented with the opportunity to acquire a personal medical advisory business that can be deployed online to serve people with medical or sports related conditions who wish to monitor the quality of clinical care they receive.

The intelligence and clinical workflow in the system had  been used over many years in tertiary care hospitals but now, due to recent progress in artificial intelligence, the system can be made available online for individuals to monitor their own clinical care.

The Company is relying on our new clinical executive, Stella Papadoukakis, in assessing this opportunity as well as other potential acquisitions in healthcare AI. We will continue to report on the progress of these negotiations.

About Blue Star Opportunities Corp

Blue Star Opportunities Corp. is now looking to expand into new lines of business that can offers a better opportunity for growth and building shareholder value. Until now, the Company has been a supplier of ecofriendly flooring materials.  More information and details on our performance can be found in our filings with OTCMarkets.com.

FORWARD-LOOKING STATEMENTS: Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management’s best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for the Company;s products and services, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

Media Contact: Michel Dab 438-501-6500